Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles

Projektinformationen

MagnoBeads

ID Finanzhilfevereinbarung: 835216

DOI

10.3030/835216

Projekt abgeschlossen

EK-Unterschriftsdatum 20 November 2018

Startdatum 1 Dezember 2018

Enddatum 31 Mai 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

HEMOTUNE AG
Switzerland

Periodic Reporting for period 1 - MagnoBeads (Removing endotoxins during sepsis: a blood purification platform using magnetic nanoparticles)

Berichtszeitraum: 2018-12-01 bis 2019-05-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Sepsis is a dysregulated immune response to infection and affects 19 million people each year. With a mortality rate of >30% for septic shock it is the most common cause of death in intensive care units. Currently, no effective cure for sepsis exits, and treatment focuses on infection control (antimicrobial agents) and supportive care (fluid resuscitation, vasopressors, ventilators and hemodialysis). Therefore, a huge societal need and market opportunity exist for curative sepsis treatments.

hemotune Ltd is a spin-off company of ETH Zurich, founded to commercialize blood purification technology for the treatment of septic shock. Hemotune is developing a blood filtration device that removes toxic particles from the blood, by employing magnetic nanoparticles that selectively bind toxic molecules and then removing them from the blood by a magnetic filter (see figure). This technology was successfully tested in small-scale animal models.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

In the MagnoBeads project, the technical and commercial feasibility of the technology were extensively evaluated. Insights were obtained regarding prototype upscaling, usability to a human scale, regulatory barriers, IP strategy and the go-to-market strategy. Based on the feasibility study, it was concluded that hemotune’s technology is both technically and commercially feasible. Moreover, technical and commercial risks were identified for which mitigation measures can now be incorporated in the business strategy.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

As a result of the MagnoBeads project, the hemotune business plan significantly matured. Based on the feasibility studies, the company has the instruments to attract further funding to finance further development to bring its technology towards the clinic. Ultimately, hemotune's technology has the potential to improve prospects for annually >300k patients suffering from septic shock in the seven main markets.